AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36597076
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ferroquine plus artefenomel 600 mg
Trial: 36597076
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ferroquine plus artefenomel 1000 mg
Trial: 36597076
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ferroquine
Trial: 36597103
Drug: Glucocorticoid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid injection into the infrapatellar fat pad (IPFP)
Trial: 36597103
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection into the infrapatellar fat pad (IPFP)
Trial: 36597115
Drug: 4-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-dose azithromycin (AZI)
Trial: 36597115
Drug: 2-dose azithromycin
RxNorm normalized name: azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-dose azithromycin (AZI)
Trial: 36597163
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2 μg/kg and ketamine 3 mg/kg
Trial: 36597543
Drug: Metformin (1,500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,500mg per day for 14 days)
Trial: 36597543
Drug: Fluvoxamine (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50mg on day one then 50mg twice daily through 14 days)
Trial: 36598621
Drug: SCTV01E vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTV01E vaccine
Trial: 36598621
Drug: D614G monovalent
RxNorm normalized name: rotavirus, monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D614G monovalent vaccine
Trial: 36598770
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) with clinician education alone.
Trial: 36599114
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with lenalidomide and dexamethasone (D-Rd)
Trial: 36599120
Drug: MR-IGABT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-IGABT with external beam radiotherapy and concurrent chemotherapy
Trial: 36599321
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of Mg
Trial: 36599321
Drug: Lower serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower serum Mg level (<1.7 mg/dL) posttreatment
Trial: 36599321
Drug: Normal serum
RxNorm normalized name: Albumin, Normal Serum, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal serum Mg level (≥1.7 mg/dL) posttreatment
Trial: 36599549
Drug: Sacubitril/Valsartan (Sac/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan (Sac/Val) therapy
Trial: 36599736
Drug: HEV 239
RxNorm normalized name: Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV 239 vaccine (two doses at 0 and 1 month)
Trial: 36599736
Drug: Control (Hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Hepatitis B virus vaccine)
Trial: 36600247
Drug: HL-085 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL-085 (12 mg twice daily)
Trial: 36600247
Drug: HL-085 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL-085 (up to 18 mg twice daily)
Trial: 36600247
Drug: HL-085 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL-085 (all doses)
Trial: 36600353
Drug: Free treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free treatment (artemisinin combination therapies (ACTs)) for positive malaria tests
Trial: 36600374
Drug: Methotrexate 10
RxNorm normalized name: methotrexate 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 10 mg once a week
Trial: 36600424
Drug: Active immunotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy with anakinra (recombinant interleukin-1 receptor antagonist) intravenously for patients with MALS
Trial: 36600424
Drug: Active immunotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy with subcutaneous recombinant human interferon-gamma for patients with immunoparalysis
Trial: 36600427
Drug: HCL-LCD (Hybrid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCL-LCD (Hybrid Closed Loop system with Low Carbohydrate Diet, <130 g carbohydrate/day) for >8 months
Trial: 36600534
Drug: Adjuvant radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiotherapy with concurrent and adjuvant durvalumab for 1 year
Trial: 36600535
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with additional manual-movement and mind-body therapies (group B)
Trial: 36600561
Drug: Mupadolimab (anti-CD73
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupadolimab (anti-CD73 antibody)
Trial: 36600670
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg daily for 14 days during induction, then 45 mg daily continuously or 30 mg daily continuously with dose reduction to 15 mg daily upon achieving complete molecular response (CMR). Maintenance therapy included daily ponatinib and vincristine-prednisone monthly for 2 years, followed by daily ponatinib indefinitely. Intrathecal injections of cytarabine and methotrexate for CNS prophylaxis.
Trial: 36600670
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events related to ponatinib and hyper-CVAD treatment.
Trial: 36601119
Drug: Lymphodepletion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepletion with fludarabine and cyclophosphamide prior to CAR-T infusion
Trial: 36601119
Drug: CLIC-1901 dose
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLIC-1901 dose infused
Trial: 36601286
Drug: Young Person's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Young Person's Face IT (YPF), an online intervention based on cognitive behavioural therapy and social skills training.
Trial: 36601956
Drug: Sacubitril/valsartan administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan administered twice daily for 52 weeks
Trial: 36601956
Drug: Enalapril administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril administered twice daily for 52 weeks
Trial: 38608693
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg/day
Trial: 36602226
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pyrotinib, letrozole, and dalpiciclib
Trial: 36602718
Drug: Topical DEX
RxNorm normalized name: Stri-Dex Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DEX (dexamethasone)
Trial: 36602718
Drug: Topical DICLO
RxNorm normalized name: Xiclo Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DICLO (diclofenac)
Trial: 36602718
Drug: Topical DEX
RxNorm normalized name: Stri-Dex Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DEX + DICLO (dexamethasone and diclofenac)
Trial: 36602718
Drug: Topical DEX
RxNorm normalized name: Stri-Dex Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DEX
Trial: 36602718
Drug: Topical DICLO
RxNorm normalized name: Xiclo Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DICLO
Trial: 36602718
Drug: Topical DEX
RxNorm normalized name: Stri-Dex Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DEX + DICLO
Trial: 36602796
Drug: gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2)
Trial: 36602796
Drug: gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) and NPC-1C (1.5 mg/kg every 2 weeks)
Trial: 36602914
Drug: Mindfulness, safety,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness, safety, and health program (self-administered, 30-minute sessions once a week for 12 weeks, using web-based learning modules and the Headspace app)
Trial: 36602927
Drug: Second-generation atypical
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation atypical antipsychotics
Trial: 36603175
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with gemcitabine and split-dose cisplatin (GC)
Trial: 36604127
Drug: Nab-paclitaxel and
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel and cisplatin administered via pressurised intraperitoneal aerosol chemotherapy (PIPAC)
Trial: 36604262
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 60,000 IU monthly
Trial: 36604756
Drug: Intravitreal sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal sirolimus and adjunct aflibercept (combination)
Trial: 36604756
Drug: Aflibercept monotherapy
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept monotherapy (control)
Trial: 36605436
Drug: Avelumab (PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab (PD-L1 antibody) combined with FOLFOX chemotherapy and cetuximab (anti-EGFR antibody)
Trial: 36606100
Drug: DAA regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAA regimen (direct-acting antiviral treatment); 8 patients started treatment
Trial: 36606536
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg administered subcutaneously for 52 weeks
Trial: 36607429
Drug: Zolbetuximab +
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab + Zoledronic Acid (ZA) + Intermediate-dose IL-2 (3 mIU) (n=7)
Trial: 36607429
Drug: Zolbetuximab +
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab + Zoledronic Acid (ZA) + Low-dose IL-2 (1 mIU) (n=9)
Trial: 36607429
Drug: Zolbetuximab +
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab + Zoledronic Acid (ZA) + IL-2 (both doses)
Trial: 36607735
Drug: PVX2 vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVX2 vaccination (twice with HPV16-targeting pNGVL4a-Sig/E7(detox)/HSP70 plasmid and once with TA-CIN protein)
Trial: 36608310
Drug: ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibrutinib 420 mg once daily plus prednisone (1 mg/kg once daily)
Trial: 36608310
Drug: ibrutinib treatment
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ibrutinib treatment
Trial: 36608320
Drug: Encorafenib 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib 450 mg once daily and binimetinib 45 mg twice daily
Trial: 36608383
Drug: Interval cytoreductive
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval cytoreductive surgery (ICS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 36608413
Drug: Sucrose (24%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (24% solution)
Trial: 36609038
Drug: DCB-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCB-based treatment
Trial: 36609038
Drug: DES-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES-only treatment
Trial: 36609046
Drug: Transdermal Glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Glyceryl Trinitrate Patches
Trial: 36609279
Drug: Intermittent Preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Preventive Treatment of malaria in schoolchildren (IPTsc) using dihydroartemisinin-piperaquine (DP) given three times a year in four-month intervals.
Trial: 36609978
Drug: rs7975232 CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs7975232 CC genotype
Trial: 36610464
Drug: Icatibant (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icatibant (30 mg doses/d for 3 consecutive days plus standard care)
Trial: 36610891
Drug: Sunitinib (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (monotherapy or combined with local treatment)
Trial: 36611210
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (maintaining hemoglobin concentrations greater than 9 g/dL)
Trial: 36611210
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (maintaining hemoglobin concentrations greater than 7 g/dL)
Trial: 36612650
Drug: Monthly telephonic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly telephonic interventions based on motivational interviewing and collaborative care strategies
Trial: 36614923
Drug: oral preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral preventive drugs
Trial: 36614923
Drug: oral preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral preventive drugs and onabotulinumtoxinA
Trial: 36615174
Drug: Aronia supplementation
RxNorm normalized name: Aronia melanocarpa fruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aronia supplementation (150 mg anthocyanins daily)
Trial: 36617389
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of insulin for a fixed range of carbohydrates (FD group)
Trial: 36617389
Drug: Precise dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precise dose of insulin for a precise number of carbohydrates using an insulin-to-carbohydrate ratio (ICR group)
Trial: 36617554
Drug: GD2-specific 4SCAR-T
RxNorm normalized name: Viral Specific T-lymphocytes
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GD2-specific 4SCAR-T cells (infused through intravenous administration alone or combined with intracavitary administration)
Trial: 36617560
Drug: Rezivertinib (BPI-7711)
RxNorm normalized name: Abivertinib
DrugBank: Abivertinib (DB15327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezivertinib (BPI-7711) 180 mg orally once daily
Trial: 36617848
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for midportion Achilles tendinopathy
Trial: 36618582
Drug: 18 G
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 G Tuohy needle
Trial: 36618582
Drug: 25 G
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 G Tuohy needle
Trial: 36618900
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg once daily, Lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle, Rituximab 375 mg/m2
Trial: 36619332
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of 57 g Jarlsberg cheese (J-group)
Trial: 36619332
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of 25-50 g Camembert (C-group)
Trial: 36619332
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of 57 g Jarlsberg cheese (after switching from C-group)
Trial: 36619630
Drug: High-dose norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose norepinephrine (≥0.3 μg/kg/min)
Trial: 36619630
Drug: Norepinephrine (≥0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (≥0.1 μg/kg/min)
Trial: 36620632
Drug: Intravenous antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibacterial prophylaxis (IV ABX) with compliance rates of 96.6% and biologic envelope hydrated in antibiotics (77.1%)
Trial: 36620632
Drug: Biologic envelope
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic envelope hydrated in antibiotics
Trial: 36620632
Drug: Antibacterial envelopes
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial envelopes without adjunct IV ABX
Trial: 36620634
Drug: Edoxaban administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban administered through PEG at approved doses
Trial: 36620770
Drug: Standard-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose atorvastatin (not specified)
Trial: 36620965
Drug: Inclisiran (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (300 mg subcutaneous, twice-yearly)
Trial: 36620965
Drug: Evolocumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (140 mg subcutaneous, every 2 weeks for 360 days, then inclisiran twice-yearly)
Trial: 36621000
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) 10 mg/kg on Days 1 and 8 of each 21-day treatment cycle until disease progression/unacceptable toxicity
Trial: 36621142
Drug: Previous systemic
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous systemic therapies (specifically protein kinase inhibitors)
Trial: 36621265
Drug: Online survey
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online survey for parents regarding recipe preparation.
Trial: 36621830
Drug: DS-1205c monotherapy
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1205c monotherapy (200-1200 mg BID) followed by combination therapy with DS-1205c (800 mg BID) and gefitinib (250 mg once daily)
Trial: 36621830
Drug: DS-1205c (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1205c (800 mg BID) in combination with gefitinib (250 mg once daily)
Trial: 36622402
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (60 mg FTD/TPI, 20 mg tablet, 3 tablets)
Trial: 36622402
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Lonsurf)
Trial: 36622462
Drug: no-basic Therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no-basic Therapy Intensity Level (TIL)
Trial: 36622462
Drug: extreme Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: extreme Therapy Intensity Level (eTIL)
Trial: 36622462
Drug: mild-moderate Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mild-moderate Therapy Intensity Level (TIL)
Trial: 36622462
Drug: Therapy Intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy Intensity Level (TIL)
Trial: 36622539
Drug: Tecarfarin 10
RxNorm normalized name: Tecarfarin
DrugBank: Tecarfarin (DB12823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecarfarin 10 mg
Trial: 36622539
Drug: Tecarfarin 20
RxNorm normalized name: Tecarfarin
DrugBank: Tecarfarin (DB12823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecarfarin 20 mg
Trial: 36622539
Drug: Tecarfarin 40
RxNorm normalized name: Tecarfarin
DrugBank: Tecarfarin (DB12823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecarfarin 40 mg
Trial: 36622539
Drug: Tecarfarin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecarfarin (all doses)
Trial: 36622653
Drug: Internet-delivered parent-child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered parent-child interaction therapy (iPCIT) for 20 weeks
Trial: 36622653
Drug: Internet-delivered parent-child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered parent-child interaction therapy (iPCIT)
Trial: 36622674
Drug: Usual pharmacy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Usual pharmacy care focused on medication adherence